Compounded medications may vary in duration, primarily when sourced from custom pharmacies
Emerging evidence demonstrates that GLP-1 receptor agonists may provide significant benefits for liver health, particularly in patients with metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as non-alcoholic fatty liver disease or NAFLD) and its inflammatory subtype, metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH)
Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients
Presented for research literature review only Finze A et al
The Body Program includes FDA-approved GLP-1s like Wegovy, Ozempic, and Zepbound, as well as compounded options (not FDA-approved, not available in some states) if insurance wont cover the brand names